Table 2.
Clinical and biochemical characteristics at the start of the study and after 24 weeks of treatment.
| Variables | Treatment (N = 37) | Placebo (N = 39) | P value* | P value† | ||||
|---|---|---|---|---|---|---|---|---|
| Week 0‡ | Week 24 | Δ 24−0 weeks | Week 0‡ | Week 24 | Δ 24−0 weeks | |||
| Body weight (kg) | 72.9 ± 10.1 | 72.4 ± 10.2 | −0.5 ± 1.6 | 71.1 ± 10.6 | 71.0 ± 10.8 | 0.1 ± 2.3 | 0.079, 0.747 | 0.419 |
| WC (cm) | 89.0 ± 7.3 | 85.8 ± 6.7 | −3.3 ± 3.6 | 87.1 ± 6.1 | 83.7 ± 6.5 | −3.4 ± 6.1 | 0.000, 0.001 | 0.890 |
| Systolic BP (mmHg) | 125.6 ± 15.5 | 124.4 ± 13.8 | −1.2 ± 11.3 | 128.3 ± 14.6 | 129.3 ± 13.8 | 1.0 ± 15.8 | 0.518, 0.710 | 0.496 |
| Diastolic BP (mmHg) | 84.1 ± 12.8 | 84.0 ± 10.7 | −0.1 ± 10.0 | 85.9 ± 13.6 | 85.2 ± 10.7 | −0.8 ± 13.9 | 0.948, 0.731 | 0.813 |
| Fasting glucose (mg/dL) | 109.9 ± 30.0 | 112.9 ± 14.9 | 3.1 ± 27.2 | 104.4 ± 16.4 | 114.5 ± 22.4 | 10.1 ± 23.4 | 0.499, 0.011 | 0.229 |
| AST (IU/L) | 22.0 ± 3.9 | 22.9 ± 4.6 | 0.9 ± 4.7 | 22.7 ± 4.1 | 25.7 ± 6.4 | 3.0 ± 5.8 | 0.246, 0.002 | 0.091 |
| ALT (IU/L) | 20.3 ± 8.5 | 22.7 ± 11.6 | 2.3 ± 10.4 | 23.5 ± 8.7 | 27.2 ± 13.3 | 3.6 ± 11.1 | 0.183, 0.049 | 0.603 |
| GGT (IU/L) | 33.0 ± 29.7 | 31.4 ± 17.6 | −1.6 ± 18.5 | 38.5 ± 25.3 | 40.3 ± 27.4 | 1.8 ± 12.6 | 0.603, 0.378 | 0.351 |
| Creatinine (mg/dL) | 0.92 ± 0.13 | 0.91 ± 0.14 | −0.01 ± 0.08 | 0.96 ± 0.13 | 0.96 ± 0.14 | −0.00 ± 0.11 | 0.290, 0.827 | 0.658 |
| Free testosterone (pg/mL) | 8.5 ± 3.2 | 9.5 ± 3.1 | 0.9 ± 3.7 | 10.9 ± 3.6 | 10.2 ± 3.4 | −0.7 ± 3.5 | 0.135, 0.235 | 0.055 |
AST: aspartate transaminase; ALT: alanine transaminase; BP: blood pressure; GGT: gamma-glutamyltransferase; WC: waist circumference.
Data are means ± SD. Δ 24-0 weeks and difference compared with baseline.
*Paired Student's t-test within group.
†Two-way repeated measures ANOVA over time between groups.